Country selection
To offer the best possible experience tailored to your national regulatory requirements and the available product portfolio, please choose your country from the following list. This option will be saved throughout the browser session. Thank you!
User experience & privacy
We use cookies to offer you an optimal website experience. This includes cookies necessary for the operation of the website and for the control of our commercial corporate goals, as well as those only used for anonymous statistical purposes, comfort settings or to display personalized content. Please note that based on your settings, not all functions of the website may be available. To find out more, please refer to our Data Privacy Statement.
27/04/2021

Eckert & Ziegler Signs Long-Term Supply Agreement with Sirtex Medical on Yttrium-90 for Treating Liver Cancer

Berlin

Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) and Sirtex Medical (Sirtex) have executed a long-term supply agreement for the use of EZAG’s Yttrium-90 in Sirtex SIR-Spheres(R) Y-90 resin microspheres for liver cancer. The arrangement has an initial term of five years and guarantees Eckert & Ziegler a substantial share of Sirtex’s rising global demand. It supplements the existing broad-based supply agreement that Sirtex and Eckert & Ziegler have been operating since 2009. The Eckert & Ziegler sales forecast for the 2021 financial year remains unaffected.

“This agreement cements our long-term relationship and makes it easier for both parties to plan accordingly. The order once again underlines our strong market position and competence as a leading production partner for the pharmaceutical industry”, explains Dr. Lutz Helmke, member of the Executive Board of Eckert & Ziegler AG and responsible for the Medical segment. “With our geographic expansion strategy, we offer our customers a reliable and worldwide supply of high-quality radioisotopes.”

“With its global manufacturing network, Eckert & Ziegler is an ideal partner for us to supply yttrium-90 worldwide. Our therapy is used in more than 50 countries to treat liver cancer, and with our recently announced prospective, multi-center study for the treatment of hepatocellular carcinoma, we have the potential to expand our FDA-approved indication for the use of SIR-Spheres(R) in the U.S.,” explains Kevin R. Smith, CEO of Sirtex Medical.

From its production facilities in Braunschweig, Germany, and Boston (MA), USA, Eckert & Ziegler supplies the Sirtex sites in Frankfurt, Boston and Singapore with yttrium-90.

Radioembolisation or selective internal radiotherapy (SIRT) uses tiny radioactive beads inserted directly into the liver tumours. The clinical data of this form of therapy, which has been used since 2002, is becoming increasingly convincing. In February 2021, the renowned British National Institute for Health and Care Excellence (NICE) issued a positive recommendation for the treatment of advanced liver carcinomas with SIR-Spheres(R) Y-90 resin microspheres. Every year, around 840,000 people worldwide develop liver cancer (source: Globocan, 2018).

To meet the increasing demand for radiopharmaceutical substances, Eckert & Ziegler is currently expanding its production sites. A new GMP facility will be added to the Boston (MA), USA site at the end of 2021. In Berlin, a new GMP facility with a total area of around 270 m² will be ready for operation in the first quarter of 2022. In Jintan (China), Eckert & Ziegler is investing up to EUR 50 million in the construction of a production facility for radiopharmaceuticals.

This expansion strategy positions Eckert & Ziegler as a global partner to the radiopharmaceutical industry, offering complete early development services, including process development and scale-up, CMC development, manufacturing and packaging, product release and stability programmes. This will enable the company to be a radiopharmaceutical contract manufacturer of phase I, II and III clinical scale products and for commercial use.

For the full press release, click here.

Contact

Get in touch

Contact us regarding your questions and we will get back to you as soon as possible.
By clicking send, you give your consent for processing your personal data in accordance with our Data Privacy Statement.
Permission required
In order to submit your request it is required to load a 3rd-party service (Google Re-Captcha spam protection system). You current privacy settings prevent this from happening automatically. By clicking the button below you explicitly allow to temporarily (on this page) load 3rd party services.